Developing a Novel Prognostic Model for Low-grade Glioma Based on m6A-Associated Immune Genes and Identifying a New Biomarker

Low-grade glioma (LGG) is a lower malignancy and slower-growing primary tumor of the nervous system. Methylation of N6-methyl adenosine (m6A) has important roles in the growth of tumors and cellular biological processes. The immune system is involved in tumourigenesis and development and plays a certain role in tumor therapy and resistance to drugs. There have been no in-depth studies on m6A-related immune markers in LGG. We obtained gene mutation data, gene expression, and related clinical information of LGG patients from the Chinese Glioma Genome Atlas (CGGA) database and the Cancer Genome Atlas (TCGA). Then, the prognostic model was calculated using multivariate Cox, LASSO, and univariate Cox analyses. A dynamic nomograph online app was also developed based on this model. In addition, for the screened model genes, we performed correlation analyses in the clinical staging, immunological subtype, and microenvironmental aspects. Finally, we determined the biological role of FBXO4 in glioma cells by quantitative reverse transcription-polymerase chain reaction, cell proliferation assay, and cell migration assay. Our prognostic models can accurately and efficiently help investigators analyze the prognosis of LGG patients. In addition, the correlation analysis between m6Ascore and tumor microenvironment can provide a basis for further exploration.